ASX-shares of Mesoblast rise on strong Ryoncil sales

Mesoblast

09/01/2026 01:20

** ASX-listed shares of Mesoblast  MSB.AX rise as much as 12.2% to A%3.310, their biggest intraday gain since November 26

** The drug-maker says sales of its cell therapy Ryoncil reached $35.1 million in December quarter, 60% higher than September quarter

** Stock among top gainers on ASX All Ordinaries index .AORD

** More than 10 million shares change hands, 2.5x the 30-day average

** MSB stock fell 12.3% in 2025

 (Reporting by Himanshi Akhand in Bengaluru)

 ((Himanshi.Akhand@thomsonreuters.com;))